Crystalline forms of a known pyrrolidine factor Xa inhibitor
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A pyrrolidinedicarboxamide and crystallization technology, applied in 1 field, can solve problems such as unpredictable results
Inactive Publication Date: 2008-03-19
WARNER LAMBERT CO LLC
View PDF1 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Finding the most stable form and such other forms is arduous and the results are unpredictable
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0103] Step 1 Preparation of (2R, 4R)-4-methoxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester
[0104] To a nitrogen purged, 500ml 3-neck flask equipped with a mechanical stirrer and thermocouple was added 60% (w / w) NaH (8g, 200mmol) and hexane (250ml). The mixture was stirred for 1 min, after which time agitation was stopped and a solid was allowed to settle. Hexane was removed using a candle filter. THF (250ml) and CH were then added to the flask 3 I (6.51ml, 105mmol) and the resulting mixture was cooled to 0°C in an ice bath. Then, (R,R)-4-hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester (22 g, 95 mmol) was added in portions while maintaining the reaction temperature at 5°C or lower. The reaction was allowed to warm to room temperature overnight. Add H to the reaction mixture 2 O (100ml), 1N HCl (100ml) and NaCl (42g). The reaction was stirred for...
Embodiment 2
[0112] From amorphous 1,2-pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridyl)phenyl]- 4-Methoxy, (2R,4R)-(9C1) Synthesis Form A.
[0113] 1.8g of amorphous 1,2-pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridyl)phenyl ]-4-Methoxy-, (2R,4R)-(9C1 ) (prepared as described by Bigge et al. in Example 150 of US2003 / 016272787) was slurried in 100 ml of water at room temperature for three days. The solid was filtered off, washed with 50 ml of water and dried under vacuum overnight to give 1.44 g of 1,2-pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo Substitute-1(2H)-pyridyl)phenyl]-4-methoxy-, (2R,4R)-(9C1). PXRD and DSC confirmed that the crystalline form was Form A.
Embodiment 3
[0115] Synthesis of Form A from Form B
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Property
Measurement
Unit
strength
aaaaa
aaaaa
strength
aaaaa
aaaaa
strength
aaaaa
aaaaa
Login to view more
Abstract
Disclosed are crystalline forms A, B and C of 1 ,2-Pyrrolidinedicarboxamide, N1 -(4- chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1 (2H)-pyridinyl)phenye]-4-methoxy-, (2R,4R)- (9Cl). These crystalline forms a re characterized by their powder X-ray diffraction, solid-state NMR, as well as methods for the preparation and pharmaceutical compositions of the same which are useful for the treatment of acute, subacute, or chronic thrombotic disorders including treatment of venous thrombosis, arterial thrombosis, pulmonary embolism, myocardial infarction, cerebral infarction, restenosis, atherosclerosis, angina, primary and secondary deep vein thrombosis, thromboembolism associated with cardiovascular disease, including, but not limited to, acute coronary syndrome, atrial fibrillation, cardiac valve replacement and deep vein thrombosis. The crystalline forms of the present invention are also useful for the treatment of cancer, sepsis and diabetes.
Description
technical field [0001] The present invention relates to 1,2-pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridyl)phenyl]- 4-Methoxy-, a crystalline form of (2R,4R)-(9C1), which exhibits inhibitory effect on the serine protease Factor Xa. In particular, the invention relates to 1,2-pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridyl)benzene ]-4-methoxy-, crystalline forms A, B and C of (2R,4R)-(9C1) and methods of using them as therapeutic agents to treat diseases in mammals characterized by abnormal thrombosis. Background technique [0002] Ischemic heart disease and cerebrovascular disease are the leading causes of death in the world. Abnormal coagulation and inappropriate thrombus formation within blood vessels contribute to many acute cardiovascular diseases. [0003] Thrombin can be considered a key or major regulatory enzyme in the coagulation cascade; it has multiple roles as a positive and negative feedback...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more